Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples